changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
MARLBOROUGH, 19 August 2019
Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE:BTG) pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com